Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial
- 195 Downloads
Complete lymph node removal through conventional axillary dissection (ALND) has been standard treatment for breast cancer patients for almost a century. In the 1990s, however, and in parallel with the advent of the sentinel lymph node (SLN) procedure, ALND came under increasing scrutiny due to its association with significant patient morbidity. Several studies have since provided evidence to suggest omission of ALND, often in favor of axillary radiation, in selected clinically node-negative, SLN-positive patients, thus supporting the current trend in clinical practice. Clinically node-positive patients, by contrast, continue to undergo ALND in many cases, if only for the lack of studies re-assessing the indication for ALND in these patients. Hence, there is a need for a clinical trial to evaluate the optimal treatment for clinically node-positive breast cancer patients in terms of surgery and radiotherapy. The TAXIS trial is designed to fill this gap by examining in particular the value of tailored axillary surgery (TAS), a new technique for selectively removing positive lymph nodes.
In this international, multicenter, phase-III, non-inferiority, randomized controlled trial (RCT), including 34 study sites from four different countries, we plan to randomize 1500 patients to either receive TAS followed by ALND and regional nodal irradiation excluding the dissected axilla, or receive TAS followed by regional nodal irradiation including the full axilla. All patients undergo adjuvant whole-breast irradiation after breast-conserving surgery and chest-wall irradiation after mastectomy. The main objective of the trial is to test the hypothesis that treatment with TAS and axillary radiotherapy is non-inferior to ALND in terms of disease-free survival of clinically node-positive breast cancer patients in the era of effective systemic therapy and extended regional nodal irradiation. The trial was activated on 31 July 2018 and the first patient was randomized on 7 August 2018.
Designed to test the hypothesis that TAS is non-inferior to ALND in terms of curing patients and preventing recurrences, yet is significantly superior in reducing patient morbidity, this trial may establish a new worldwide treatment standard in breast cancer surgery. If found to be non-inferior to standard treatment, TAS may significantly contribute to reduce morbidity in breast cancer patients by avoiding surgical overtreatment.
KeywordsBreast cancer surgery Axillary lymph node dissection Clinically node-positive Tailored axillary surgery Axillary radiotherapy Overall survival Disease-free survival Quality of life
American Joint Committee on Cancer
Axillary lymph node dissection
Breast cancer-specific survival
Case report form
Common Terminology Criteria for Adverse Events
Clinical target volume
External dosimetry audit
Electronic Data Capture
European Clinical Trials Database
Functional Assessment of Cancer Therapy-Breast
Good Clinical Practice
Invasive breast cancer recurrence-free interval
International Council on Harmonization
Individual case review
National Cancer Institute
Organs at risk
Positron emission tomography
Planning risk volume
Planning target volume
Quality of life
Regional recurrence rate
Regional nodal irradiation
Radiotherapy quality assurance
- SAKK CC
SAKK Coordinating Center
Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
Sentinel lymph node
Sentinel lymph node biopsy
Standard operating procedure
Surgical site infections
Targeted axillary dissection
Tailored axillary surgery
Union for International Cancer Control
World Health Organization
Disease and therapy background
Worldwide more than 2 million patients are diagnosed with breast cancer every year . It accounts for one third of all cancer diagnoses among women, and causes more than 600,000 deaths per year. Still about 1200 patients per year in Switzerland need axillary lymph node dissection (ALND) as part of their surgical treatment. ALND is indicated primarily for node-positive breast cancer. Patients are identified either by pre-operative evaluation of the axilla or by intraoperative sentinel lymph node biopsy (SLNB).
The trial findings supported the current trend in clinical practice toward decreased rates of axillary dissection in patients with non-palpable axillary lymph node metastases [17, 18] and showed that axillary radiation is a valid alternative to dissection in selected patients.
The important landmark trial ACOSOG Z0011 has been criticized for several reasons. One limitation of ACOSOG Z0011 was the lack of standardization and detailed documentation of adjuvant radiation fields and the angles of the tangents, which makes it impossible to know how much of the axilla was irradiated . Since the no-axillary dissection arm in Z0011 was categorized as “no further axillary treatment” and defined by “no axillary dissection and no third-field nodal irradiation,” this question became relevant. However, an attempt to reconstruct the radiation fields of Z0011 resulted in the receipt of only 30% of detailed radiotherapy (RT) records for centralized review, and produced evidence of improperly applied axilla irradiation in at least 20% of cases .
In parallel with the trend toward less axillary surgery, radiation oncologists have been broadening the indication for extended regional lymph node irradiation based on evidence from two large phase-III trials showing improved disease-free survival (DFS) [21, 22, 23] and a large population-based cohort study showing improved overall survival  in node-positive patients after ALND. In addition, recent data from the latest Early Breast Cancer Trialists’ Collaborative Group meta-analysis confirmed that post-mastectomy radiotherapy (PMRT) for patients with one to three positive nodes reduced recurrence and breast cancer mortality . If given, PMRT includes the chest wall and regional nodes in most patients . Consequently, the optimal contemporary loco-regional management of node-positive patients has become controversial, while ALND remains standard of care for patients with high-volume (i.e., large tumor load in the lymph nodes) or treatment-resistant nodal disease (i.e., residual disease in the lymph nodes after neoadjuvant systemic therapy).
Ongoing clinical trials in axillary surgery 
Italy: SOUND IEO S637/311 NCT02167490
SLN vs. observation
Germany: INSEMA NCT02466737
1. SLN vs. observation
2. 1–2 SLN+ → ALND vs. no ALND
France: SERC/IPC 2012–001 DNCT01717131
ALND vs. no ALND
China: Z0011-China NCT01796444
ALND vs. no ALND
Sweden: SENOMAC NCT02240472
ALND vs. no ALND
United Kingdom: POSNOC NCT02401685
ALND or axillary radiotherapy vs. no axillary treatment
Netherlands: BOOG 2013–07 NCT02112682
ALND or axillary radiotherapy vs. no axillary treatment
USA: Alliance A011202 NCT01901094
ALND+ extended regional nodal irradiation vs. axillary radiotherapy + extended regional nodal irradiation
Several other ongoing randomized controlled trials primarily aim at validating the Z0011 protocol in different countries with several minor protocol modifications (Z0011-China, SERC/IPC 2012–001 in France, SENOMAC in Sweden, POSNOC in the United Kingdom, BOOG 2013–07 in the Netherlands).
POSNOC allows axillary RT as an alternative to ALND in the control arm. Similarly, BOOG 2013–07 allows axillary RT or ALND to complete axillary treatment in the control arm, but includes patients with one to three positive SLN undergoing mastectomy . Since the Z0011 study population is not included in our proposed trial, there is no or only minimal overlap between these trials and the present protocol.
The most progressive ongoing clinical trial on axillary management, partially overlapping with the proposed protocol, is Alliance A011202. It compares ALND with axillary radiation in patients with residual disease after chemotherapy, which was an exclusion criterion in both the AMAROS and the Z0011 trials. The trial tests the hypothesis that the AMAROS protocol in combination with extended regional nodal irradiation works in these patients without ALND to the extent that chemotherapy-resistant lymph node metastases are as radiosensitive as chemotherapy-naive disease.
The optimal treatment of the regional lymph nodes in clinically node-positive patients is currently unclear, with less surgery, more RT or a combination thereof being under discussion. In the era of increasing post-mastectomy and extended regional node irradiation as well as effective systemic therapy, the indication for ALND in patients with clinically positive nodes and confirmed disease at the time of surgery has to be investigated in a clinical trial. Most of the above-mentioned trials excluded patients with residual metastases after neoadjuvant chemotherapy, and the omission of axillary dissection in patients with imaging-detected lymph node metastases is controversial since they may predict a larger volume of axillary disease [28, 29, 30, 31, 32].
Rationale for performing the trial
TAXIS is designed to determine whether ALND may be no longer necessary for confirmed nodal disease at first diagnosis of breast cancer given the prevalence of extended regional nodal irradiation in clinically node-positive patients in the adjuvant setting or incomplete response of nodal disease in the neoadjuvant setting. In many patients undergoing ALND, the number of negative lymph nodes removed exceeds the number of tumor-affected nodes. Removing multiple unaffected lymph nodes increases morbidity with no therapeutic benefit. It is a consequence of the commitment of radical surgery to the principle of complete tissue removal within the anatomical borders of the axilla. Benefits and harms of this approach must be re-assessed. TAXIS investigates tailored axillary surgery (TAS), a tailored approach focusing on the removal of tumor-affected lymph nodes while limiting the extent of surgery to minimize the number of negative nodes removed. TAS may offer non-inferior oncological outcomes with less morbidity than ALND in patients with clinically positive nodes at first presentation and confirmed nodal disease at surgery with or without neoadjuvant therapy.
Trial design, sites, and duration
The main objective of the trial is to test the hypothesis that treatment with TAS and axillary radiotherapy (RT) is non-inferior to axillary lymph node dissection (ALND) in terms of DFS of breast cancer patients with positive nodes at first presentation in the era of effective systemic therapy and extended regional nodal irradiation.
Recruitment and consent
Prior to enrollment, eligible patients are informed about the aims, procedures and possible risks of the trial, as well as its confidentiality policy regarding patient data, and are given sufficient opportunity and time to consider whether or not to participate. All patients are made aware that participation is voluntary and that they are allowed to refuse further participation in the trial whenever they want. Written informed consent is obtained from each patient before enrollment and prior to any trial-specific procedures.
Eligible for inclusion in this trial are female and male patients aged ≥ 18 years if they meet the following criteria:
Node-positivity detected by imaging (iN+) and confirmed by pathology or detected by palpation (cN1–2) and confirmed by pathology
Node-positivity initially detected by imaging (negative on palpation) and residual disease intraoperatively confirmed by pathology (in SLN or non-SLN during surgery) in case of neoadjuvant treatment
Node-positivity initially detected by palpation and residual disease intraoperatively confirmed by pathology in case of neoadjuvant treatment
Eligible for primary ALND or SLN procedure with frozen section and either (1) newly diagnosed or (2) isolated in-breast recurrence or second ipsilateral breast cancer (at least 5 years disease free and no prior axillary surgery or loco-regional RT)
Most suspicious axillary lymph node clipped
Adequate condition for general anesthesia and breast cancer surgery
Ability to understand and complete the quality of life (QoL) questionnaire
WHO performance status 0–2
Stage IV breast cancer
Clinical N3 breast cancer
Clinical N2 breast cancer (if limited to the internal mammary nodes only)
Contralateral breast cancer
Prior axillary surgery (except prior sentinel node procedure in case of in-breast recurrence)
Prior regional RT
History of hematological or primary solid tumor malignancy, unless in remission for at least 5 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
Concurrent treatment with any experimental drug within 30 days of pre-registration
Concomitant use of other anticancer drugs or RT
Patients are, furthermore, excluded if they have any serious underlying medical, psychiatric, psychological, familial or geographical condition, which, in the judgment of the investigator, may interfere with the planned staging, treatment, and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
- Type of positive node detection:
○ Node-positivity detected by imaging (iN+) and confirmed by pathology
○ Node-positivity detected by palpation (cN1–2) and confirmed by pathology
○ Node-positivity initially detected by imaging (negative on palpation) and residual disease confirmed by pathology (in SLN or non-SLN during surgery) after neoadjuvant treatment
○ Node-positivity initially detected by palpation and residual disease confirmed by pathology after neoadjuvant treatment
Newly diagnosed vs. isolated in-breast recurrence or second ipsilateral breast cancer (at least 5 years disease free and no prior axillary surgery or loco-regional RT)
Normofractionated vs. hypofractionated RT
Male / female patient
Randomization is usually performed during the breast surgery as soon as the operating surgeon has certified that all inclusion criteria are met, including in particular the pathological confirmation of node-positivity and residual disease for patients who had received neoadjuvant treatment. If node-positivity cannot be confirmed on frozen section during primary surgery, the randomization takes place as soon as possible after the positive pathology results are available. Randomization is exclusively done online by using the centralized electronic data capture system secuTrial®. Patients who are not randomized will not enter into the trial and no further data will be collected except retrospective data for the two subprojects described in section “Performance characteristics of TAS” and “Patterns of use of neoadjuvant systemic treatment” of Appendix 3. Those patients will be treated according to the current best standard of care according to investigator’s decision, which commonly involves ALND.
Investigational trial treatment
The investigational trial treatment consists of tailored axillary surgery (TAS), which is defined by the SLN procedure in combination with the selective removal of all palpable disease and documentation of the removal of the initially biopsy-proven and clipped lymph node metastasis by specimen radiography. If the clip is not documented in the specimen radiography, the patient is excluded and undergoes ALND.
All patients undergo adjuvant whole-breast irradiation after breast-conserving surgery and chest-wall irradiation after mastectomy. While patients allocated to arm A (control arm) receive regional nodal irradiation excluding the dissected axilla as a target volume (levels (II)/III; medial supraclavicular; internal mammary lymph nodes), patients allocated to arm B (investigational arm) receive regional nodal irradiation including the full axilla (levels I–III; medial supraclavicular; internal mammary lymph nodes).
If indicated, patients may undergo adjuvant systemic treatment.
Tailored axillary surgery
A video of the intervention has been uploaded as Additional file 1.
Additional file 1: Video S1. (MP4 383974 kb).
All patients undergo breast-conserving surgery or mastectomy and the SLN procedure. The SLN procedure should preferably be performed by dual mapping, which includes all nodes that are either blue (blue dye), hot (technetium Tc-99 m), fluorescent (indocyanine green) or magnetic (superparamagnetic iron oxide particles), according to local SLN procedure practices. In addition to the removal of the sentinel nodes, all palpably suspicious nodes, defined as either hardened or irregular or very large or a combination thereof, are removed.
Surgical evaluation of the levels I–III by palpation is mandatory to ensure that there is no palpably suspicious disease left behind in the axilla after TAS. The length of the incision and the opening of the clavipectoral fascia has to be chosen accordingly. Therefore, a minimum incision length of 2–3 cm is recommended. In case of palpably suspicious nodes left behind in the axilla after TAS, the patient must be excluded und typically undergoes ALND according to the decision of the treating surgeon.
Surgeons who perform the SLN procedure as part of their clinical routine are allowed to perform TAS. TAS is feasible for all surgeons who master the SLN procedure since the only difference is the selective removal of palpable disease, which we expect to be a frequent step in the clinically node-positive patient population of this trial. However, thorough palpation of the axilla is also mandatory during the regular SLN procedure in current clinical practice to remove suspicious findings and minimize the false-negative rate. The difference is that during the regular SLN procedure that is performed as a staging procedure, this step is rarely necessary since it is only performed in clinically node-negative patients.
The selective removal of the clipped lymph node by image-guided localization, a procedure increasingly referred to as targeted axillary dissection (TAD), is encouraged to increase the chances of successful clip removal. However, TAD is not a mandatory part of TAS, since it is technically challenging and, therefore, quite controversial, and the clipped lymph node corresponds to one of the SLNs in the majority of patients. TAD has recently emerged as an effective strategy to reduce the false-negative rate of the SLN procedure in patients with initially confirmed node-positive breast cancer that showed a complete clinical response in the nodes after neoadjuvant treatment. The metastatic node is marked with a clip during biopsy, or shortly after the lymph node metastasis has been confirmed by pathology or cytology, and is then selectively localized and removed during the procedure [35, 36, 37]. Any method is allowed for localization of the clipped node, such as the use of wire, iodine-125 or magnetic seeds, radioguided occult-lesion localization, ultrasound or a tattoo [35, 36, 37, 38, 39, 40, 41]. If the clip is not documented in the specimen radiography, the patient is excluded and undergoes ALND, since confirmation of the removal of the lymph node with the initially biopsy proven is not possible.
Importantly, residual suspicious lymph nodes detected by imaging before the end of adjuvant treatment does neither demand nor prohibit take-back surgery for completion ALND or selective removal of these nodes or an additional RT boost. The study group is fully aware that some patients will have non-palpable residual disease in the axilla after TAS. The hypothesis of TAXIS is that this residual disease does not progress to recurrence. The clinical scenario of residual disease after axillary surgery detected by imaging, i.e., performed for RT treatment planning or staging, to rule out distant disease, has become more frequent after implementation of the ACOSOG Z0011 and the EORTC-AMAROS protocols . Histological evaluation and adjustment of axillary treatment (such as completion ALND, selective removal of suspicious nodes or additional RT boost) are allowed and interdisciplinary consensus-based decisions are encouraged.
Axillary lymph node dissection
After randomization, the patients in arm A will be treated according to the current standard of care by ALND. ALND is defined by the intention of the surgeon to radically remove the entire soft tissue within the anatomical borders of the axilla. To ensure applicability of the findings of the present study to clinical practice, we purposefully refrained from further defining the exact technique or number of removed lymph nodes. One common way to perform ALND is described here. Standard ALND clears levels I and II. A clip may be applied by the surgeon to mark the medial border of dissection, commonly between levels II and III, and documented in the surgical report. A full level-III dissection above the pectoralis minor muscle is carried out when there is gross nodal disease. The latissimus dorsi muscle is identified and followed until it is crossed by the axillary vein. The surface of the vein is then cleared of fat. Dissection inferior to the vein is carried out, dividing the fat and controlling the branches of the axillary vein entering the specimen. The thoracodorsal bundle is the deep lateral branch. Once identified, the pectoralis minor is retracted and the level-III nodes are dissected – if indicated – from the space below the axillary vein. The long thoracic nerve is identified against the chest wall and dissected free from the specimen. The fat between the thoracodorsal and long thoracic nerves is encircled with a clip or bipolar vessel-sealing system, divided, and bluntly swept inferiorly. Branches of the thoracodorsal vessels entering the specimen are dissected, and the specimen is freed from its remaining attachments to the inferior chest wall. A closed suction drain is standard care for most surgeons. The dermis is re-approximated and the skin is closed.
All patients undergo adjuvant whole-breast irradiation after breast-conserving surgery or chest-wall irradiation after mastectomy, as well as regional nodal irradiation, excluding the dissected axilla as a target volume in arm A (levels (II)/III; medial supraclavicular; internal mammary lymph nodes) and including the full axilla (levels I–III; medial supraclavicular; internal mammary lymph nodes) as a target volume in arm B. In case of extensive nodular involvement in arm A, the target volume includes the area at risk of the dissected levels. Inclusion of internal mammary nodes is recommended in this high-risk group of patients irrespective of treatment arm . RT should start preferably within 8 weeks from the last breast surgical procedure and not later than 12 weeks. In case chemotherapy was applied, RT should start within 6 weeks after the end of the last cycle of chemotherapy and not later than 8 weeks. Dose to the breast/thoracic wall as well as the regional nodal pathways: 50 Gy in 25 fractions of 2 Gy or 50.4 Gy in 28 fractions of 1.8 Gy; daily, 5 days a week. Hypofractionated schedule allowed: 40 Gy in 15 fractions of 2.67 Gy to the same volume.
For a detailed description of RT, see Appendix 6.
Adjuvant systemic treatment
Where adjuvant systemic anticancer treatment is indicated, all drugs to be used are locally chosen according to international guidelines, including the sequence of systemic therapy in relation to surgery (neoadjuvant vs. adjuvant setting) [43, 44]. Handling of chemotherapy, anti-HER2 treatment and endocrine therapy is subject to the approved product information in each respective country. The decision of the indication of adjuvant chemotherapy could be different in the two treatment arms, because of a higher number of lymph nodes removed in arm A (ALND) compared to the group with TAS only. However, this belongs to a strategic trial like this and cannot be avoided with pre-defined rules in the protocol.
For a description of all evaluations performed before, during, and after the trial treatment, see Appendix 1.
Local recurrence, regional recurrence, distant recurrence
Second breast cancer
Death from any cause
Patients not experiencing an event will be censored at the date of the last available assessment.
The primary objective is to compare patient-reported arm problems in the short (after 9 months), intermediate (after 24 months), and long term (after 60 and 120 months) in breast cancer patients with clinically positive nodal disease in the era of extended regional nodal irradiation who are randomized to TAS followed by axillary radiation vs. TAS followed by ALND. The primary QoL endpoint is the change in the ARM subscale of the FACT-B + 4 from baseline to 24 months after randomization [45, 46].
Secondary objectives include the comparison of (1) short-, intermediate-, and long-term QoL and of (2) short-, intermediate-, and long-term effect of arm problems on daily and social activities between randomized groups.
Breast cancer-specific survival
Time to local recurrence
Time to regional recurrence
Time to distant recurrence
- Physician-reported morbidity outcomes
○ Lymphedema: the change in ipsilateral upper-extremity circumference, corrected for any change in the contralateral upper extremity, will be calculated using the following formula:
where I indicates ipsilateral upper-extremity circumference, C indicates contralateral upper-extremity circumference, a indicates assessments during trial treatment and follow-up, and b indicates baseline assessment. L will be calculated for both upper arm and forearm, and lymphedema is defined as present if L > 2 cm for either location. The proportion of patients with lymphedema will be calculated at each assessment
○ Decreased range of shoulder motion: the change in shoulder motion (flexion, abduction, internal rotation, and external rotation) assessed by goniometric measurement of arm movement (Appendix 6) on both sides will be calculated for each assessment
Adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03
Late RT-related AEs
Surgical site infections (SSI)
SSI will be assessed according to the Centers for Disease Control and Prevention Surgical Site Infection Classification System.
Immune profile of axillary lymph nodes
Evaluation of the prognostic value of multigene tests
Performance characteristics of TAS
Patterns of use of neoadjuvant systemic treatment
Impact of TAS on adjuvant systemic treatment decisions
Quality assessment of delineation and dose planning and impact on treatment outcomes in adjuvant RT
Impact of a bolus on outcome and RT-related AEs in patients with mastectomy
For a detailed description of the subprojects, see Appendix 3.
Sample size considerations and statistical analyses
The sample size is based on the primary endpoint DFS. With a type I error of 5% and a power of 80%, 385 events will be needed to show non-inferiority of TAS and axillary RT in comparison to ALND with a non-inferiority hazard ratio of 1.289 (corresponding to a DFS at 5 years of 80% in the ALND arm and 75% in the TAS and axillary RT arm). The sample size needed is 1500 patients (750 per arm). One interim analysis for efficacy/futility is foreseen after 20% of the required events have occurred. A report including the interim efficacy results as well as patient characteristics, treatment administration and safety results (AEs, SSI, and serious AEs) will be presented to an independent Data Monitoring Committee appointed by the SAKK Board. The SAKK Board will decide on the continuation/modification/early stopping of the trial based on the recommendations of the committee. All efficacy endpoints will be analyzed based on the per-protocol set. For the primary endpoint, DFS, the hazard ratio and one-sided 95% confidence interval will be calculated using a Cox regression model with the treatment arm as independent variable and the stratification factors as strata. The median DFS and the corresponding 95% confidence intervals using the Kaplan-Meier method will be presented for each treatment arm.
Type of positive node detection at first diagnosis: cN1 vs. iN1
Neoadjuvant vs. adjuvant systemic treatment vs. both
ycN1 vs. ycN0
BMI < 25 kg/m2 vs ≥ 25 kg/m2
Normofractionation vs. hypofractionation
Breast-conserving surgery vs. mastectomy
Triple-negative vs. HER2+ vs. ER- and/or PR-positive, and HER2-
Handling of missing data and drop-outs
No imputation of missing data will be performed. A row denoted “Missing” will be included in count tabulations if necessary to account for drop-outs and missing values. For continuous variables a column with the number of available observations will be added. Patients lost to follow-up before reaching the primary endpoint will not be replaced.
Reporting of adverse events
Any AE related to the clipping of the most suspicious axillary lymph node and
Specific AEs related to the trial surgical procedure or the RT (possible, probable, definite) as pre-defined in the original trial protocol
The investigator assesses and records the AEs observed during the AE-reporting period: from the date of patient consent signature up to 20 years after randomization of the last patient. However, no AEs related to neoadjuvant and/or adjuvant systemic therapy will be reported.
Study management and administration
For a description of the study management and administration, see Appendix 4.
For a description of the study documentation, see Appendix 5.
Designed to test the hypothesis that TAS in combination with RT is non-inferior to ALND in terms of curing patients and preventing recurrences, yet is significantly superior in terms of patient morbidity, this trial has the potential to establish a new worldwide treatment standard in breast cancer surgery. If found to be non-inferior to standard treatment, TAS may contribute significantly to reduce morbidity in breast cancer patients by avoiding surgical overtreatment. For the SPIRIT checklist applicable to this study protocol, see Additional file 2.
Protocol no: SAKK 23/16 / IBCSG 57–18 / ABCSG-53
Protocol version: final version 1.0, 6 April 2018
EudraCT no: 2018–000372-14
Trial type: clinical trial with other health intervention
Categorization: risk category B according to the Swiss Human Research Act and its ordinance KlinV/Oclin
Trial sponsor: SAKK (Swiss Group for Clinical Cancer Research), Effingerstrasse 33, 3008 Bern, Switzerland
TAXIS was registered at ClinicalTrials.gov, on 1 May 2018, under NCT03513614 and on the Swiss National Clinical Trials Portal (SNCTP) at www.kofam.ch/de/studienportal/suche/38529/studie/42266, on 17 June 2018, under NCT03513614.
The trial was activated on 31 July 2018. The first patient was randomized on 7 August 2018.
Patient information and consent to participate
The informed consent procedure is in compliance with the Swiss law and the guidelines on GCP issued by the ICH. All patients will be informed of the aims and procedures of the trial, the possible AEs, how to react in case an AE occurs, and possible hazards to which they will be exposed. They will be informed as to the strict confidentiality of their patient data, but they need to know that their medical records may be reviewed for trial purposes by authorized individuals other than their treating physician. The investigator provides each patient with sufficient opportunity and time to consider whether or not to participate and minimize the possibility of coercion or undue influence. The information provided will be in a language intelligible to the patient and may not include any content that appears to waive any of the patient’s legal rights, or appears to release the investigator, the sponsor, or the institution from liability for negligence. It will be emphasized that participation is voluntary and that the patient is allowed to refuse further participation in the trial whenever they want. This will not prejudice the patient’s subsequent care. Informed consent is obtained before enrollment and prior to any protocol-specific procedures. Informed consent is obtained on a written form approved by the local Ethics Committee (EC) and signed and personally dated by the patient and the investigator. The patient information, as well as a copy or original of the signed and dated informed consent, is handed to the patient. In case new results become available that shift the risk/benefit ratio, the patient should re-consent.
Patients have the right to discontinue their participation in the trial for any reason and at any time, without prejudice to further treatment. Patients who refuse further trial treatment will be transferred to the follow-up phase and continue to receive the follow-up assessments as scheduled. Patients who withdraw their consent (i.e., refuse further data collection), will be informed that all data collected until the time point of their withdrawal will be kept coded and used. For the patient’s security, a final examination should be performed. Patients may be withdrawn at any time from trial treatment at the discretion of the treating physician or the investigator due to a serious AE, or based on any other relevant medical condition. The patient then will be transferred to the follow-up phase and continue to receive the follow-up assessments as scheduled.
Trial-related data of the patient will be provided in a coded manner to the SAKK Communicating Centre (SAKK CC). The names of the patients will not be disclosed to the SAKK CC. A unique patient number will be attributed to each patient registered into the trial at time of pre-registration. Identification of patients will be guaranteed at the site. For this purpose, sites are requested to use the patient screening and enrollment and the patient identification lists specifically produced for the trial (available on the SAKK website). In order to avoid identification errors, the year of birth and the unique patient number must be provided on the case report forms (CRFs). Patient confidentiality will be maintained according to applicable legislation. Patients must be informed of, and agree to, data and material transfer and handling, in accordance with local data protection law.
The SAKK will indemnify patients for damages that they have suffered as participants in the trial. For this purpose, SAKK has taken out a special insurance for clinical trials with Chubb Insurance (Switzerland) Ltd., Bärengasse 32, 8001 Zürich.
Fond’Action, Rising Tide Foundation for Clinical Cancer Research, Krebsliga beider Basel and Swiss Cancer Research are supporting in part this trial. Additional coverage over the course of the trial is planned. For that, applications to small foundations in Switzerland and foreign countries will be done from now and re-applications to major donors will be performed in Switzerland 3 years after opening of accrual. The outstanding amount will be covered by research agreements with the following institutions: SERI, Swiss Cancer Research Foundation and Swiss Cancer League.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
WPW is the principal coordinating investigator and conceived the idea and design of the trial; he is also the coordinator of the two subprojects “Performance characteristics of tailored axillary surgery” and “Patterns of use of neoadjuvant systemic treatment.” MK is the supporting coordinating investigator of the trial and the coordinator of the subproject ‘Evaluation of the prognostic value of multigene tests’. FF, ZM, and BB are the national principal investigators at the study sites in Austria, Hungary and Italy, respectively. GH and DRZ are the radiation oncologist representatives of the trial; GH is also responsible for the quality assurance of RT and the coordinator of the subproject “Quality assessment of delineation and dose planning and impact on treatment outcomes in adjuvant RT.” TR is the medical oncologist representative of the trial. SM is the main trial pathologist. MA is the coordinator of the subproject “Immune profile of axillary lymph nodes.” CK is the coordinator of the subproject “Impact of tailored axillary surgery on adjuvant systemic treatment.” SH is the main trial statistician and responsible for all statistical analyses. MAG is the clinical project manager. MG is the ABCSG representative. KR is the IBCSG representative and responsible for all matters concerning QoL. All authors contributed to the drafting of the manuscript and have read and approved its final version.
Ethics approval and consent to participate
The TAXIS study protocol SAKK 23/16 – IBCSG 57–18 – ABCSG-53, the patient information and consent form, as well as all other trial-related documents have been approved by the Lead EC for Northwest/Central Switzerland (EKNZ) in agreement with local legal requirements for formal authorization. The Lead EC authorization number is: 2018–00838. Any amendment to the protocol or patient information and consent form will be submitted for authorization to these institutions. Any substantial amendment to the protocol (except for safety reasons) can only be implemented at a site after obtaining written authorization by the corresponding regulatory bodies.
Patient recruitment only took place after the site had officially been opened for accrual by the SAKK CC. Sites in Switzerland have to adhere to the Swiss Human Research Act and all applicable local regulatory guidelines. Sites in foreign countries have to adhere to national law and locally applicable regulatory guidelines. Central ethical approval has been confirmed from the Lead EC for Northwest/Central Switzerland (authorization number: 2018–00838) and we will not begin recruiting at other centers in the trial until local ethical approval has been obtained.
TAXIS is carried out in accordance with the principles enunciated in the current version of the Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) issued by the ICH, the applicable Swiss Human Research Act and its associated ordinances and the requirements from the Swiss and European regulatory bodies [47, 48, 49, 50, 51, 52, 53].
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.EUCAN. http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. Accessed 06 Apr 2018.
- 7.Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32.PubMedPubMedCentralGoogle Scholar
- 13.Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla — Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672–9.CrossRefPubMedGoogle Scholar
- 31.Pilewskie M, Mautner SK, Stempel M, Eaton A, Morrow M. Does a positive axillary lymph node needle biopsy result predict the need for an axillary lymph node dissection in clinically node-negative breast cancer patients in the ACOSOG Z0011 era? Ann Surg Oncol. 2016;23(4):1123-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Union for International Cancer Control (UICC). TNM Classification of Malignant Tumours. Ed. by Brierley JD, Gospodarowicz MK, Wittekind C. 8th Edition. Oxford, UK ; Hoboken, NJ: John Wiley & Sons, Inc., 2017.Google Scholar
- 35.Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results fom ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802-7.Google Scholar
- 36.Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Siso C, de Torres J, Esgueva-Colmenarejo A, et al. Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA Trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol. 2018;25(3):784-91.CrossRefPubMedGoogle Scholar
- 39.NCCN Guidelines. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 06 Apr 2018.
- 42.S3 Guideline. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/. Accessed 06 Apr 2018.
- 43.Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700–12.Google Scholar
- 47.Verordnung über klinische Versuche mit Heilmitteln (VKlin) vom 17. Oktober 2001 (Stand am 1. Januar 2008)/Ordonnance sur les essais cliniques de produits thérapeutiques (OClin) du 1 juillet 2004 (Etat le 1er janvier 2008). (https://www.admin.ch/opc/de/classified-compilation/20011140/200409010000/812.214.2.pdf). Accessed 06 Apr 2018.
- 48.Declaration of Helsinki (as amended in Tokyo, Venice, Hong Kong, Somerset West, Edinburgh and Seoul, and clarified in Washington and Tokyo). 2008, October. (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-researchinvolving-human-subjects/).
- 49.HRA. Bundesgesetz über die Forschung am Menschen (Humanforschungsgesetz, HFG) vom 30. September 2011 (Stand am 1. Januar 2014) / Loi fédérale relative à la recherche sur l'être humain (Loi relative à la recherche sur l'être humain, LRH) du 30 septembre 2011 (Etat le 1er janvier 2014), 810.30. In: Goverment, editor.: http://www.admin.ch/opc/de/official-compilation/2013/3215.pdf. Accessed 06 Apr 2018.
- 50.Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. 2008;34(5):508–13.CrossRefPubMedGoogle Scholar
- 51.Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279–93.CrossRefPubMedGoogle Scholar
- 53.Directive 2001/20/EC of the European Parliament and of the Council. 2001. http://www.eortc.be/Services/Doc/clinical-EU-directive-04-April-01.pdf. Accessed 06 Apr 2018.
- 57.Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28(25):3929–36.CrossRefPubMedPubMedCentralGoogle Scholar
- 71.Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677–83.CrossRefPubMedPubMedCentralGoogle Scholar
- 72.Solin LJ, Gray R, Goldstein LJ, et al. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat. 2012;134(2):683–92.CrossRefPubMedPubMedCentralGoogle Scholar
- 76.RISAS Procedure in Node Positive Breast Cancer Following NAC. https://clinicaltrials.gov/ct2/show/NCT02800317.
- 77.SenTa: Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD). https://clinicaltrials.gov/ct2/show/study/NCT03102307. Accessed 06 Apr 2018.
- 93.Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) (ICRU Report 83). https://icru.org/testing/reports/prescribing-recording-and-reporting-intensity-modulated-photon-beam-therapy-imrt-icru-report-83.
- 94.The SKAGEN Trial 1: moderately hypofractionated loco-regional adjuvant radiation therapy of early breast cancer combined with a simultaneous integrated boost in patients with an indication for boost: DBCG HYPO II, a randomised clinically controlled trial. https://clinicaltrials.gov/ct2/show/NCT02384733. Accessed 06 Apr 2018.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.